We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

22 hedge funds and large institutions have $25.2M invested in Aldeyra Therapeutics in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

8% less funds holding

Funds holding: 24 → 22 (-2)

23% less capital invested

Capital invested by funds: $32.9M → $25.2M (-$7.61M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
8
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PA
Perceptive Advisors
New York
+$683K
2
JP Morgan Chase
JP Morgan Chase
New York
+$497K
3
WMSA
Weiss Multi-Strategy Advisers
New York
+$457K
4
NIP
Nicholas Investment Partners
California
+$179K
5
Morgan Stanley
Morgan Stanley
New York
+$31.2K

Top Sellers

1
SM
Sabby Management
Florida
-$1.03M
2
SIM
Spark Investment Management
New York
-$28.1K
3
Millennium Management
Millennium Management
New York
-$22.6K
4
IF
Ironwood Financial
Arizona
-$4K
5
Walleye Trading
Walleye Trading
New York
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$8.38M – – –
PA
2
Perceptive Advisors
New York
$5.58M +$683K +87,393 +10%
DM
3
Deerfield Management
New York
$4.03M – – –
SFM
4
Sphera Funds Management
Israel
$1.54M – – –
BBA
5
Baker Bros. Advisors
New York
$828K – – –
KCM
6
Knoll Capital Management
Florida
$792K – – –
SM
7
Sabby Management
Florida
$787K -$1.03M -131,956 -49%
Millennium Management
8
Millennium Management
New York
$677K -$22.6K -2,900 -2%
Vanguard Group
9
Vanguard Group
Pennsylvania
$626K +$29.7K +3,800 +4%
WMSA
10
Weiss Multi-Strategy Advisers
New York
$443K +$457K +58,500 +334%
NIP
11
Nicholas Investment Partners
California
$371K +$179K +22,878 +56%
JP Morgan Chase
12
JP Morgan Chase
New York
$371K +$497K +63,605 New
PVI
13
Pura Vida Investments
New York
$335K – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$131K – – –
Morgan Stanley
15
Morgan Stanley
New York
$119K +$31.2K +3,992 +24%
SIM
16
Spark Investment Management
New York
$105K -$28.1K -3,600 -16%
Northern Trust
17
Northern Trust
Illinois
$71K +$9.21K +1,180 +11%
BA
18
BlackRock Advisors
Delaware
$17K +$14K +1,794 +152%
VIA
19
Vantage Investment Advisors
Pennsylvania
$12K – – –
UBS Group
20
UBS Group
Switzerland
$9K -$2.6K -333 -17%
TRCT
21
Tower Research Capital (TRC)
New York
$8K +$8.47K +1,085 +493%
BIM
22
BlackRock Investment Management
Delaware
$6K – – –
IF
23
Ironwood Financial
Arizona
– -$4K -500 Closed
Walleye Trading
24
Walleye Trading
New York
– -$3K -400 Closed

ALDX Hedge Fund Activity: Q3 2015 in Review

22 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2015, worth a combined $25.2M — down 23% from $32.9M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ALDX and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 8 added.

The largest buyer was Perceptive Advisors, adding an estimated $683K. The largest seller was Sabby Management, cutting an estimated $1.03M.

  • 22 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2015, down from 24 in Q2 2015.
  • Funds reported $25.2M of Aldeyra Therapeutics stock for Q3 2015, down 23% quarter-over-quarter.
  • 1 fund opened new Aldeyra Therapeutics positions in Q3 2015 and 3 closed out, a net change of -2 holders.
  • The largest Aldeyra Therapeutics buyer in Q3 2015 was Perceptive Advisors, an estimated $683K added.
  • The largest Aldeyra Therapeutics seller in Q3 2015 was Sabby Management, an estimated $1.03M sold.

Based on aggregated 13F filings for Q3 2015.